_:n64ee83aa7c744719bb01b68c44b5cb3bxb0
<http://schema.org/articleBody>
"Representatives of several small and medium pharma companies have suggested that the government adopt a \"one molecule-one MRP\" formula instead of trade margin rationalisation (TMR) on non-scheduled drugs to reduce their prices. They are planning to take up this during a meeting called by union minister for health and chemicals and fertilisers Mansukh Mandaviya with industry representatives on Tuesday. The government is geared up to apply the TMR formula on non-scheduled drugs.As reported by ET earlier, the National Pharmaceutical Pricing Authority (NPPA), India's price regulatory authority, in May restarted discussions with the stakeholders on the matter. The previous round of talks had happened in November 2019. Trade margin is the difference between the price at which manufacturers/importers sell products to stockists and the price charged to consumers. At present, the NPPA fixes the price of scheduled drugs. Prices of non-scheduled drugs are allowed to be increased by as much as 10% a year.Tuesday's meeting will likely be attended by the Laghu Udyog Bharati, Federation of Pharma Entrepreneurs, Himachal Drug Manufacturers Association, and the Indian Federation of Pharma Generics, among others. \"We request the government to find out another way and apply a uniform formula for all segments,\" said Rajesh Gupta, the all India head of the Laghu Udyog Bharati.Follow and connect with us on Twitter, Facebook, Linkedin, Youtube"
<https://health.economictimes.indiatimes.com/news/pharma/pharma-bodies-bat-for-one-molecule-one-mrp-policy/93122470>